title: Reply to "Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?" by Wei et al.
authors.affiliation: Department of Orthopaedic Surgery, Duke University Medical Center.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Olson
authors.affiliation: Department of Orthopaedic Surgery, Duke University Medical Center.
authors.forename: Bridgette D
authors.initials: BD
authors.lastname: Furman
authors.affiliation: Duke Molecular Physiology Institute.|Department of Medicine, Duke University School of Medicine.
authors.forename: Virginia B
authors.initials: VB
authors.lastname: Kraus
authors.affiliation: Department of Medicine, Duke University School of Medicine.
authors.forename: Janet L
authors.initials: JL
authors.lastname: Huebner
authors.affiliation: Laszlo Ormandy Professor and Vice-Chair of Orthopaedic Surgery, Departments of Orthopaedic Surgery, Biomedical Engineering, Mechanical Engineering & Materials Science, and Cell Biology.
authors.forename: Farshid
authors.initials: F
authors.lastname: Guilak
mesh_terms: D000818:Animals; D001168:Arthritis / Q000503:physiopathology* / Q000517:prevention & control*; D057072:Intra-Articular Fractures / Q000150:complications*; D007596:Joints / Q000503:physiopathology*; D008297:Male; D010003:Osteoarthritis / Q000378:metabolism*; D013583:Synovial Membrane / Q000378:metabolism*